EUCTR2005-006029-94-BE进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 720
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age 45 – 80 years, inclusive
- •Males or Females (women of child-bearing potential must use adequate protection)
- •Confirmed coronary artery disease defined as one of the following:
- •- Post-ACS or MI or Post PCI (greater than 4 weeks) or
- •- CABG (greater than 12 weeks) or
- •- Angina pectoris with documented (ECG or imaging study) ischemia or
- •- Angiographically documented lesion occluding =70% of a coronary vessel
- •And at high risk as defined by one or more of the following:
- •Screening hsCRP = 3.0 mg/L
- •History of diabetes mellitus under Rx treatment
- •Documented history of peripheral arterial disease
- •Documented history of Thrombo-embolic TIA or stroke greater than 1 year prior to screening
- •Documented history of Carotid artery disease
- •All subjects must be receiving low-dose (75-325 mg) aspirin and or clopidogrel 75 mg once daily. Ticlopidine 250mg twice daily with or without low dose aspirin once daily is also allowed. These medications must be taken for at least 1 month prior to screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Unwilling or unable to provide informed consent
- •History of acquired or congenital bleeding disorder, coagulopathy, or platelet disorder
- •Recent trauma or major surgery in the past 30 days prior to Screening
- •Evidence of active pathological bleeding at screening or history of bleeding (such as gastrointestinal or genitourinary) within the 6 months prior to Screening, unless the cause has been definitely corrected
- •History of intracranial bleeding (eg, hemorrhagic stroke, subdural hematoma, subarachnoid hemorrhage) or history of hemorrhagic retinopathy
- •History of ischemic stroke or transient ischemic attack within the past year prior to Screening or known structural cerebral vascular lesion (eg, arterial venous malformation, aneurysm)
- •Hematological abnormalities: INR >1.5 or PTT >1.5 X ULN, Platelet count
- •<100 x (10)3/µL (<100 x (10)9/L), Hemoglobin <10 g/dL at Screening
- •History of New York Heart Association class 3 or 4 congestive heart failure or history of severe, uncontrolled cardiac arrhythmias at Screening
- •Significant (as determined by the Investigator) cardiovascular events in the 30 days prior to the Screening Visit or newly prescribed or dose adjustments made to cardiovascular medications in the 30 days prior to the Screening Visit
- •Planned elective surgical operation or major invasive procedure from 30 days before screening to completion of the study (The decision of what constitutes a major invasive procedure will be at the discretion of the investigator in conjunction with review and approval by the medical monitor)
- •Unstable diabetes requiring frequent adjustments to medications (other than insulin) in the 30 days prior to the Baseline Visit
- •Documented history of chronic liver disease and/or Screening ALT or AST >3 x ULN or Total Bilirubin >1.5 x ULN (unless the abnormal bilirubin level is secondary to Gilbert’s syndrome)
- •Documented presence of rheumatologic or autoimmune diseases requiring continuous treatment with anti-inflammatory agents
- •Significant renal impairment, defined as creatinine clearance <30 mL/min
- •History of cancer (other than basal cell carcinoma of the skin, cervical carcinoma in situ, or low-grade prostate cancer), unless adequately treated with no evidence of disease recurrence for at least 2 years
- •Recent (within 14 days prior to Baseline Visit) significant infection or history of chronic infections with a recurrence <14 days prior to the Screening Visit and/or requiring continuous antibiotic treatment
- •Use of any of the following drugs in the 30 days prior to Screening and for the duration of the study:
- •- Oral anti-thrombotics other than low dose aspirin (daily aspirin dose of 325 mg
- •or lower) and/or clopidogrel (75 mg) and/or ticlopidine (250 mg bid)
- •- Anticoagulants (eg, coumadin, warfarin)
- •- Fibrinolytics (eg, TPA, streptokinase, urokinase)
- •- NSAIDs, other than occasional use
- •- COX-2 inhibitors, other than occasional use
- •- Potent and moderate CYP (global) 3A4 inhibitors
- •- Selected CYP 2D6 substrates
- •- Herbals with antiplatelet properties: Gingko biloba, Horse chestnut
- •(Aesculus hippocastanum)
- •Use of another investigational drug within 30 days prior to the Screening Visit or use of an investigational device (eg, unapproved stent) within 12 weeks prior to the Screening Visit
- •Pregnant, or nursing women.
- •use of illicit drugs or alcohol abuse 3 months prior to the screening or during the course of the study.
研究者
相似试验
进行中（未招募）
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中（未招募）
1 期
A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia (CAH)MedDRA version: 20.0Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000004850EUCTR2019-004873-17-DEeurocrine Biosciences, Inc.165
进行中（未招募）
1 期
Clinical Trial to compare if seriously-ill adults with constipation due to narcotics have bowel movements sooner after injection with Methylnatrexone or placeboEUCTR2007-000854-30-BESalix Pharmaceuticals Inc254
进行中（未招募）
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82